International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
Dean M. Wingerchuk,Brenda Banwell,Jeffrey Bennett,Philippe Cabre,William M. Carroll,Tanuja Chitnis,Jérôme De Seze,Kazuo Fujihara,Benjamin Greenberg,Anu Jacob,Sven Jarius,Marco Aurélio Lana-Peixoto,Michael J. Levy,Jack H. Simon,Silvia Tenembaum,Anthony Traboulsee,Patrick Waters,Kay E. Wellik,Brian G. Weinshenker +18 more
Reads0
Chats0
TLDR
The International Panel for NMO Diagnosis (IPND) was convened to develop revised diagnostic criteria using systematic literature reviews and electronic surveys to facilitate consensus and achieved consensus on pediatric NMOSD diagnosis and the concepts of monophasicNMOSD and opticospinal MS.Abstract:
Neuromyelitis optica (NMO) is an inflammatory CNS syndrome distinct from multiple sclerosis (MS) that is associated with serum aquaporin-4 immunoglobulin G antibodies (AQP4-IgG). Prior NMO diagnostic criteria required optic nerve and spinal cord involvement but more restricted or more extensive CNS involvement may occur. The International Panel for NMO Diagnosis (IPND) was convened to develop revised diagnostic criteria using systematic literature reviews and electronic surveys to facilitate consensus. The new nomenclature defines the unifying term NMO spectrum disorders (NMOSD), which is stratified further by serologic testing (NMOSD with or without AQP4-IgG). The core clinical characteristics required for patients with NMOSD with AQP4-IgG include clinical syndromes or MRI findings related to optic nerve, spinal cord, area postrema, other brainstem, diencephalic, or cerebral presentations. More stringent clinical criteria, with additional neuroimaging findings, are required for diagnosis of NMOSD without AQP4-IgG or when serologic testing is unavailable. The IPND also proposed validation strategies and achieved consensus on pediatric NMOSD diagnosis and the concepts of monophasic NMOSD and opticospinal MS.read more
Citations
More filters
Journal ArticleDOI
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
Alan J. Thompson,Brenda Banwell,Frederik Barkhof,Frederik Barkhof,William M. Carroll,Timothy Coetzee,Giancarlo Comi,Jorge Correale,Franz Fazekas,Massimo Filippi,Mark S. Freedman,Kazuo Fujihara,Steven L. Galetta,Hans-Peter Hartung,Ludwig Kappos,Fred D. Lublin,Ruth Ann Marrie,Aaron E. Miller,David Miller,Xavier Montalban,Xavier Montalban,Ellen M. Mowry,Per Soelberg Sørensen,Mar Tintoré,Anthony Traboulsee,Maria Trojano,Bernard M. J. Uitdehaag,Sandra Vukusic,Sandra Vukusic,Emmanuelle Waubant,Brian G. Weinshenker,Stephen C. Reingold,Jeffrey A. Cohen +32 more
TL;DR: The 2017 McDonald criteria continue to apply primarily to patients experiencing a typical clinically isolated syndrome, define what is needed to fulfil dissemination in time and space of lesions in the CNS, and stress the need for no better explanation for the presentation.
Journal ArticleDOI
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice—Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Sixth Special Issue
Joseph E. Schwartz,Jeffrey L. Winters,Anand Padmanabhan,Rasheed A. Balogun,Meghan Delaney,Michael L. Linenberger,Zbigniew M. Szczepiorkowski,Mark E. Williams,Yanyun Wu,Beth H. Shaz +9 more
TL;DR: The Eighth Edition of the JCA Special Issue seeks to continue to serve as a key resource that guides the utilization of TA in the treatment of human disease.
Journal ArticleDOI
MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome
Sven Jarius,Klemens Ruprecht,Ingo Kleiter,Nadja Borisow,Nasrin Asgari,Kalliopi Pitarokoili,Florence Pache,Oliver Stich,Lena-Alexandra Beume,Martin W. Hümmert,Marius Ringelstein,Corinna Trebst,Alexander Winkelmann,Alexander Schwarz,Mathias Buttmann,Hanna Zimmermann,Joseph Kuchling,Diego Franciotta,Marco Capobianco,Eberhard Siebert,Carsten Lukas,Mirjam Korporal-Kuhnke,Jürgen Haas,Kai Fechner,Alexander U. Brandt,Kathrin Schanda,Orhan Aktas,Friedemann Paul,Markus Reindl,Brigitte Wildemann +29 more
TL;DR: The predominantly relapsing and often severe disease course and the short median time to second attack support the use of prophylactic long-term treatments in patients with MOG-IgG-positive ON and/or myelitis; however, treatment failure leading to rapid accumulation of disability was noted in many patients as well as flare-ups after steroid withdrawal.
Journal ArticleDOI
MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines.
Massimo Filippi,Maria A. Rocca,Olga Ciccarelli,Olga Ciccarelli,Nicola De Stefano,Nikos Evangelou,Ludwig Kappos,Alex Rovira,Jaume Sastre-Garriga,Mar Tintoré,Jette L. Frederiksen,Claudio Gasperini,Jacqueline Palace,Daniel S. Reich,Brenda Banwell,Xavier Montalban,Frederik Barkhof +16 more
TL;DR: State-of-the-art MRI findings in patients presenting with a clinically isolated syndrome were discussed in a MAGNIMS workshop, the goal of which was to provide an evidence-based and expert-opinion consensus on diagnostic MRI criteria modifications.
Journal ArticleDOI
International consensus diagnostic criteria for neuromyelitis optica spectrum disordersAuthor Response
TL;DR: Criteria for neuromyelitis optica (NMO) spectrum disorders (NMOSD) was proposed that incorporated unifying the terms NMO and NMOSD, including patients with aquaporin-4 (AQP4)–immunoglobulin G (IgG) negative/unknown, thus giving these patients …
References
More filters
Journal ArticleDOI
Long-term Follow-up of Acute Partial Transverse Myelitis
Bertrand Bourre,Hélène Zéphir,Jean-Claude Ongagna,Charlotte Cordonnier,Nicolas Collongues,Stéphanie Debette,Marie-Céline Fleury,Olivier Outteryck,Didier Hannequin,Patrick Vermersch,Jérôme De Seze +10 more
TL;DR: This study confirms that abnormal brain MRI results and the presence of oligoclonal bands in CSF are 2 independent predictive factors for conversion to MS.
Journal ArticleDOI
CNS aquaporin-4 autoimmunity in children
TL;DR: The study suggested that G2019S mutation carriers might be more likely to develop levodoparelated dyskinesias than patients without this mutation, but although several genes have been suggested to confer a genetic predisposition to levodopa-induced motor complications, a similar role for the LRRK2 G 2019S mutation, suggested by the study, needs further confirmation.
Journal ArticleDOI
Neuromyelitis optica IgG serostatus in fulminant central nervous system inflammatory demyelinating disease.
Setty M. Magaña,Sean J. Pittock,Vanda A. Lennon,B. Mark Keegan,Brian G. Weinshenker,Claudia F. Lucchinetti +5 more
TL;DR: This study is the first to compare NMO IgG serostatus among patients with fulminant central nervous system inflammatory demyelinating disease (CNS IDD) and concludes that N MO IgG is a specific biomarker for NMO spectrum disorders and is not simply a marker of destructive CNS IDD.
Journal ArticleDOI
Epidemiologic and clinical studies of multiple sclerosis in Japan.
TL;DR: No. 1 No. 1 as discussed by the authors ) is the best one. And No. 2 No. 3 No. 4 No. 5 No. 6 No. 7 No. 10
Related Papers (5)
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
Chris H. Polman,Stephen C. Reingold,Brenda Banwell,Michel Clanet,Jeffrey A. Cohen,Massimo Filippi,Kazuo Fujihara,Eva Havrdova,Michael Hutchinson,Ludwig Kappos,Fred D. Lublin,Xavier Montalban,Paul L. O’Connor,Magnhild Sandberg-Wollheim,Alan J. Thompson,Emmanuelle Waubant,Brian G. Weinshenker,Jerry S. Wolinsky +17 more